Gilead To Present Idelalisib Phase 3 Study At American Society Of Hematology

(RTTNews) - Gilead Sciences, Inc. (GILD), Monday said its Phase 3 study evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia patients who were not fit for chemotherapy was accepted for presentation during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in New Orleans. Detailed results from the study will be presented on Decmber 10.

The study was stopped early, in October, based on a pre-specified interim analysis performed by an external Data Monitoring Committee, demonstarting a highly statistically significant effect on the primary endpoint of progression-free survival. Safety was in line with previous observations, and was largely consistent with advanced disease patients receiving CD20 antibody therapy, the company said.